| [1] |
RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79( 6): 1542- 1556. DOI: 10.1016/j.jhep.2023.06.003. |
| [2] |
YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/hep.0000000000000004. |
| [3] |
MANTHEY J, SHIELD KD, RYLETT M, et al. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: A modelling study[J]. Lancet, 2019, 393( 10190): 2493- 2502. DOI: 10.1016/S0140-6736(18)32744-2. |
| [4] |
SHI GX, QIAN YS, JIANG CM, et al. Prevalence of steatotic liver disease(MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents[J]. Sci Rep, 2024, 14: 25724. DOI: 10.1038/s41598-024-76922-9. |
| [5] |
ISRAELSEN M, TORP N, JOHANSEN S, et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: An analysis of data from a prospective cohort study[J]. Lancet Gastroenterol Hepatol, 2024, 9( 3): 218- 228. DOI: 10.1016/S2468-1253(23)00443-0. |
| [6] |
JOHN BV, BASTAICH D, MEZZACAPPA C, et al. Identifying metabolic dysfunction-associated steatotic liver disease using natural language processing in a US national cohort[J]. Am J Gastroenterol, 2025, 120( 11): 2583- 2591. DOI: 10.14309/ajg.0000000000003321. |
| [7] |
JEON S, CARR R. Alcohol effects on hepatic lipid metabolism[J]. J Lipid Res, 2020, 61( 4): 470- 479. DOI: 10.1194/jlr.r119000547. |
| [8] |
FAN L, ZHU XZ, ZHANG XY, et al. Magnesium depletion score and mortality in individuals with metabolic dysfunction associated steatotic liver disease over a Median follow-up of 26 years[J]. Nutrients, 2025, 17( 2): 244. DOI: 10.3390/nu17020244. |
| [9] |
GOMMERS LMM, HOENDEROP JGJ, BINDELS RJM, et al. Hypomagnesemia in type 2 diabetes: A vicious circle?[J]. Diabetes, 2016, 65( 1): 3- 13. DOI: 10.2337/db15-1028. |
| [10] |
JOKINEN MJ, LUUKKONEN PK. Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease[J]. Trends Pharmacol Sci, 2024, 45( 4): 319- 334. DOI: 10.1016/j.tips.2024.02.003. |
| [11] |
DING ZB, ERICKSEN RE, ESCANDE-BEILLARD N, et al. Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis[J]. J Hepatol, 2020, 72( 4): 725- 735. DOI: 10.1016/j.jhep.2019.10.026. |
| [12] |
LUUKKONEN PK, DUFOUR S, LYU K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease[J]. Proc Natl Acad Sci U S A, 2020, 117( 13): 7347- 7354. DOI: 10.1073/pnas.1922344117. |
| [13] |
JEW MH, HSU CL. Alcohol, the gut microbiome, and liver disease[J]. J Gastro And Hepatol, 2023, 38( 8): 1205- 1210. DOI: 10.1111/jgh.16199. |
| [14] |
RAYA TONETTI F, EGUILEOR A, MRDJEN M, et al. Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease[J]. Hepatology, 2024, 80( 6): 1342- 1371. DOI: 10.1097/hep.0000000-000000924. |
| [15] |
YUAN J, CHEN C, CUI JH, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae[J]. Cell Metab, 2019, 30( 4): 675- 688. e 7. DOI: 10.1016/j.cmet.2019.08.018. |
| [16] |
DUAN HY, GONG MM, YUAN G, et al. Sex hormone: A potential target at treating female metabolic dysfunction-associated steatotic liver disease?[J]. J Clin Exp Hepatol, 2025, 15( 2): 102459. DOI: 10.1016/j.jceh.2024.102459. |
| [17] |
STAUFER K, HUBER-SCHÖNAUER U, STREBINGER G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease[J]. J Hepatol, 2022, 77( 4): 918- 930. DOI: 10.1016/j.jhep.2022.04.040. |
| [18] |
MORINAGA M, KON K, UCHIYAMA A, et al. Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease[J]. Hepatol Int, 2022, 16( 2): 348- 358. DOI: 10.1007/s12072-022-10298-8. |
| [19] |
NGUYEN VL, PAULL P, HABER PS, et al. Evaluation of a novel method for the analysis of alcohol biomarkers: Ethyl glucuronide, ethyl sulfate and phosphatidylethanol[J]. Alcohol, 2018, 67: 7- 13. DOI: 10.1016/j.alcohol.2017.08.009. |
| [20] |
TAVAGLIONE F, AMANGURBANOVA M, YANG AH, et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: A prospective study[J]. Aliment Pharmacol Ther, 2025, 61( 6): 1043- 1054. DOI: 10.1111/apt.18506. |
| [21] |
ARAB JP, DÍAZ LA, REHM J, et al. Metabolic dysfunction and alcohol-related liver disease(MetALD): Position statement by an expert panel on alcohol-related liver disease[J]. J Hepatol, 2025, 82( 4): 744- 756. DOI: 10.1016/j.jhep.2024.11.028. |
| [22] |
FINANGER T, MELBY K, SPIGSET O, et al. Relationship between alcohol intake based on daily smartphone-reported consumption and PEth concentrations in healthy volunteers[J]. Alcohol Alcohol, 2024, 59( 4): agae040. DOI: 10.1093/alcalc/agae040. |
| [23] |
GRANT BF, CHOU SP, SAHA TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: Results from the national epidemiologic survey on alcohol and related conditions[J]. JAMA Psychiatry, 2017, 74( 9): 911- 923. DOI: 10.1001/jamapsychiatry.2017.2161. |
| [24] |
RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/hep.0000000000000323. |
| [25] |
SOOKOIAN S, PIROLA CJ. Resmetirom for treatment of MASH[J]. Cell, 2024, 187( 12): 2897- 2897. e 1. DOI: 10.1016/j.cell.2024.05.009. |
| [26] |
HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom(MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394( 10213): 2012- 2024. DOI: 10.1016/S0140-6736(19)32517-6. |
| [27] |
HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390( 6): 497- 509. DOI: 10.1056/nejmoa2309000. |
| [28] |
YU ST, RAO S, REDDY JK. Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis[J]. Curr Mol Med, 2003, 3( 6): 561- 572. DOI: 10.2174/1566524033479537. |
| [29] |
RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome Proliferator-Activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150( 5): 1147- 1159. e 5. DOI: 10.1053/j.gastro.2016.01.038. |
| [30] |
KOIZUMI A, KAJI K, NISHIMURA N, et al. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease[J]. World J Gastroenterol, 2024, 30( 28): 3428- 3446. DOI: 10.3748/wjg.v30.i28.3428. |
| [31] |
ARMSTRONG MJ, HULL D, GUO K, et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis[J]. J Hepatol, 2016, 64( 2): 399- 408. DOI: 10.1016/j.jhep.2015.08.038. |
| [32] |
NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384( 12): 1113- 1124. DOI: 10.1056/nejmoa20-28395. |
| [33] |
SANYAL AJ, NEWSOME PN, KLIERS I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis[J]. N Engl J Med, 2025, 392( 21): 2089- 2099. DOI: 10.1056/nejmoa2413258. |
| [34] |
MUDALIAR S, HENRY RR, SANYAL AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease[J]. Gastroenterology, 2013, 145( 3): 574- 582. e 1. DOI: 10.1053/j.gastro.2013.05.042. |
| [35] |
PATEL K, HARRISON SA, ELKHASHAB M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial[J]. Hepatology, 2020, 72( 1): 58- 71. DOI: 10.1002/hep.31205. |
| [36] |
BAJAJ JS, GAVIS EA, FAGAN A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder[J]. Hepatology, 2021, 73( 5): 1688- 1700. DOI: 10.1002/hep.31496. |
| [37] |
LI F, ZHANG ZY, BAI Y, et al. Glucosamine improves non-alcoholic fatty liver disease induced by high-fat and high-sugar diet through regulating intestinal barrier function, liver inflammation, and lipid metabolism[J]. Molecules, 2023, 28( 19): 6918. DOI: 10.3390/molecules28196918. |
| [38] |
RYU T, CHANG Y, YOO JJ, et al. Glucosamine supplementation attenuates progression of metabolic dysfunction-associated steatotic liver disease and related comorbidities[J]. Clin Nutr, 2025, 47: 119- 128. DOI: 10.1016/j.clnu.2025.02.012. |
| [39] |
NATARAJ K, SCHONFELD M, RODRIGUEZ A, et al. Protective role of 17β-estradiol in alcohol-associated liver fibrosis is mediated by suppression of integrin signaling[J]. Hepatol Commun, 2024, 8( 5): e0428. DOI: 10.1097/hc9.0000000000000428 |
| [40] |
BENEDÉ-UBIETO R, ESTÉVEZ-VÁZQUEZ O, GUO FF, et al. An experimental DUAL model of advanced liver damage[J]. Hepatol Commun, 2021, 5( 6): 1051- 1068. DOI: 10.1002/hep4.1698. |
| [41] |
BABUTA M, MOREL C, DE CARVALHO RIBEIRO M, et al. A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis[J]. Hepatol Commun, 2024, 8( 7): e0450. DOI: 10.1097/hc9.0000000000000450 |
DownLoad: